HOME >> BIOLOGY >> NEWS
Blooming health thanks to a frog

As published in the October 15th issue of Genes & Development, Dr. Hong Yan and his team at Fox Chase Cancer Center in Philadelphia detail their use of frogs to investigate how the gene defective in patients with Bloom's Syndrome works. Bloom's Syndrome is associated with the development of tumors early in life, usually in the twenties. Bloom's Syndrome is a rare genetic disease which is most frequently found among Ashkenazi Jews. These patients are predisposed to develop all types of the cancer. Understanding the molecular mechanisms beneath Bloom's Syndrome is an important goal to help to fight cancer.

The gene defective in Bloom's Syndrome enables additional mutations to occur. This gene belongs to the helicases, a class of proteins known to unwind double stranded DNA during replication and repair. In order to identify the exact role of this protein, Dr. Yan and colleagues turned to the species Xenopus, a frog firmly established as a biological model system. They used extracts from Xenopus eggs to reconstitute a cell-free system of DNA replication. After identifying the frog version of the Bloom's Syndrome protein, the team used specific antibodies to remove the protein from the system. They discovered that the Bloom's Syndrome protein is essential for DNA replication in Xenopus. It is likey that the protein will have the same function in humans. Turning to a frog sometimes really leads to royal results.


'"/>

Contact: Nora Poppito
poppito@cshlorg
Cold Spring Harbor Laboratory
14-Oct-2000


Page: 1

Related biology news :

1. New IU Bloomington life sciences building gets a name
2. Genetic modification of linseed produces healthier omega 3 and 6 fatty acids
3. Chemical signals health of brain cells Symposium
4. The birth of reproductive health: A difficult delivery
5. Ventilation in bars, casinos doesnt control health risk for hospitality workers
6. Diabetics face fewer healthy food choices in some urban areas
7. Human health risks in space flight focus of research internships
8. Study shows impact of emotionally healthy fathers when mothers poor mental health affects children
9. Ottawas leadership in biomedical and health research has paid off
10. Oxygen sensing in worms may hold key to healthy blood pressure in humans
11. Make a splash for public health this summer

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Blooming health thanks frog

(Date:11/21/2014)... According to a new market research report ... Control, Intrusion Detection, Parking Management, Under Vehicle Inspection), End ... - Global Forecasts to 2020", published by MarketsandMarkets, The ... $25 Billion in 2014 and is expected to reach ... 8.69%. Browse 116 market data Tables and ...
(Date:11/21/2014)... JOSE, Calif. , Nov. 20, 2014   ... global leader in microcontroller (MCU) and touch technology solutions, ... digital temperature sensors with the widest V cc ... delivers higher temperature accuracy and faster I 2 C ... registers and serial EEPROM memory making them ideal for ...
(Date:11/18/2014)... YORK , Nov. 18, 2014   ... identity authentication solutions, and MorphoTrust USA ... and services, today announced a strategic partnership to ... enterprise, motor vehicle administration (MVA), airport screening and ... in identity-related solutions, MorphoTrust serves consumers through a ...
Breaking Biology News(10 mins):Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
(Date:12/17/2014)... Ipsen Biopharmaceuticals, Inc., an affiliate ... IPSEY), today announced that Somatuline® Depot® (lanreotide) ... approved by the U.S. Food and Drug Administration ... (GEP-NETs) in adult patients with unresectable, well or ... improve progression-free survival (PFS). , “The approval of ...
(Date:12/17/2014)... IN (PRWEB) December 17, 2014 ... Laboratory Excellence following its most recent COLA inspection. ... by COLA, a national healthcare accreditation organization. Accreditation ... standards of quality in day-to-day operations, demonstrate continued ... pass a rigorous on-site laboratory survey. ...
(Date:12/17/2014)... 2014  Vermillion, Inc. (NASDAQ: VRML ), ... announced the next step in its expanded strategy to ... with the naming of current Chief Operating Officer, ... while current Chairman of the Board and CEO ... These changes are effective January 1, 2015. ...
(Date:12/17/2014)... 17, 2014 Tigercat Pharma, Inc. today ... evaluating the investigational oral NK-1 receptor antagonist VPD-737 ... chronic itch who are unresponsive or inadequately responsive ... steroids and antihistamines. The primary ... Scale (VAS) itch score from baseline, comparing drug ...
Breaking Biology Technology:Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4
Cached News: